These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28274396)

  • 1. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
    Toesca DAS; Pollom EL; Poullos PD; Flynt L; Cui Y; Quon A; von Eyben R; Koong AC; Chang DT
    Pract Radiat Oncol; 2017; 7(2):120-125. PubMed ID: 28274396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
    Pastis NJ; Greer TJ; Tanner NT; Wahlquist AE; Gordon LL; Sharma AK; Koch NC; Silvestri GA
    Chest; 2014 Aug; 146(2):406-411. PubMed ID: 24577678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
    Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
    Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
    Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
    Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
    Dholakia AS; Chaudhry M; Leal JP; Chang DT; Raman SP; Hacker-Prietz A; Su Z; Pai J; Oteiza KE; Griffith ME; Wahl RL; Tryggestad E; Pawlik T; Laheru DA; Wolfgang CL; Koong AC; Herman JM
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):539-46. PubMed ID: 24751410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
    Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
    Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Characteristics and Use of Pretherapeutic 18 F-Fluorodeoxyglucose-PET for Pancreatic Cancer.
    Carlson DM; Abdelrahman AM; Adjei Antwi SK; Tomlinson JL; Trivedi K; Karbhari A; Patnam Gopal Chetty N; Halfdanarson TR; Goenka AH; Truty MJ
    J Am Coll Surg; 2024 Jul; 239(1):9-17. PubMed ID: 38445645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
    Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
    Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients.
    Huang YS; Chen JL; Hsu FM; Huang JY; Ko WC; Chen YC; Jaw FS; Yen RF; Chang YC
    J Magn Reson Imaging; 2018 Jan; 47(1):191-199. PubMed ID: 28480541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
    Kim YI; Kim SK; Paeng JC; Lee HY
    Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.
    Daamen LA; Groot VP; Goense L; Wessels FJ; Borel Rinkes IH; Intven MPW; van Santvoort HC; Molenaar IQ
    Eur J Radiol; 2018 Sep; 106():128-136. PubMed ID: 30150034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study.
    Solanki AA; Weichselbaum RR; Appelbaum D; Farrey K; Yenice KM; Chmura SJ; Salama JK
    Radiat Oncol; 2012 Dec; 7():216. PubMed ID: 23244066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of
    Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
    Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
    Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET.
    Higashi T; Sakahara H; Torizuka T; Nakamoto Y; Kanamori S; Hiraoka M; Imamura M; Nishimura Y; Tamaki N; Konishi J
    J Nucl Med; 1999 Sep; 40(9):1424-33. PubMed ID: 10492360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.